AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04194203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
Study NCT04194203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
Study NCT04194203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered by IV infusion at a dose of 175 mg/m2.
Study NCT04194203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered by IV infusion at a dose of 175 mg/m2.
Study NCT04194203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered by IV infusion at a dose of 500 mg/m2.
Study NCT04194203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed will be administered by IV infusion at a dose of 500 mg/m2.
Study NCT04194203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered by IV infusion to achieve an initial target AUC of 6 mg/mL/min.
Study NCT04194203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered by IV infusion to achieve an initial target AUC of 6 mg/mL/min.
Study NCT04502446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX130
Description: CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
Study NCT04457830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F520
Description: 3mg/kg every 3 weeks
Study NCT01722760 — intervention group
Intervention type: PROCEDURE
Intervention: measurements
Study NCT02123602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stabilization
Study NCT02123602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lower extremity training only
Study NCT03311282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: infants bottles
Description: * angled/inclined teat that remains full of milk throughout the feeding to prevent the risk of air ingestion, gassy colic, hiccups and regurgitation and to keep the infant's neck in the right position;~* extra-large, soft and rounded base to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion~* flexors at the base to enhance elasticity and flexibility of the teat
Study NCT03311282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infants Bottles
Description: * large, rounded and soft teat to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion~* non-inclined shape of the teat ideal from 4 months onwards, when the colic episodes have subsided and infant has more control of the neck.~* flexors at the base to enhance elasticity and flexibility of the teat
Study NCT03311282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infants Bottles
Description: * teat with less rounded base to guarantee tighter lip support, which helps the sucking motion.~* flexors at the base to enhance elasticity and flexibility of the teat
Study NCT02416492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB623 cells
Description: SB623 cells will be implanted in the peri-infarct area using stereotactic surgery.
Study NCT02416492 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Sham Surgery
Study NCT01690130 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (Neuronetics)
Description: Transcranial magnetic stimulation is a noninvasive brain stimulation that can focally stimulate the brain of an awake individual. A TMS pulse focally stimulates the cortex by depolarizing superficial neurons which induces electrical currents in the brain.
Study NCT01690130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (Neuronetics)
Description: Transcranial magnetic stimulation is a noninvasive brain stimulation that can focally stimulate the brain of an awake individual. A TMS pulse focally stimulates the cortex by depolarizing superficial neurons which induces electrical currents in the brain.
Study NCT01690130 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS.The sham-TMS scalp discomfort will be matched to that of active TMS.
Study NCT01690130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Transcranial Magnetic Stimulation
Description: The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS.The sham-TMS scalp discomfort will be matched to that of active TMS.
Study NCT03213652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03213652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo a bone marrow aspiration and/or biopsy
Study NCT03213652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo a bone scan
Study NCT03213652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan
Study NCT03213652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Given PO
Study NCT03213652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03213652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03213652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03213652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo a PET scan
Study NCT03213652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo radionuclide imaging
Study NCT03213652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray
Study NCT00663325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic acid (Dermacid)
Description: Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
Study NCT01505387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Litramine
Description: Fibre complex of plant origin in tablet form 2 tablets 3 times daily (oral consumption, after meal)
Study NCT01505387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical to Litramine tablets 2 tablets 3 times daily (oral consumption, after meal)
Study NCT02324387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Molecular Breast Imaging (MBI)
Description: Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled neoadjuvant chemotherapy (NAC) treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
Study NCT02033525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XCEL-M-ALPHA and standard rehabilitation
Description: Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)
Study NCT02324387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m sestamibi
Description: 8 mCi of 99mTc sestamibi by vein before each molecular breast imaging (MBI).
Study NCT00858533 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health at Work workplace health advice and support
Description: The intervention group will receive additional support from a H@W Workplace Health Advisor who will deliver an intervention aimed at sickness absence prevention or sustained return to work, depending on individual circumstances. The intervention will be standardized as far as possible to show types of activity undertaken with participants, their GP, line managers, human resources departments and trade union representatives.
Study NCT02521142 — intervention group
Intervention type: OTHER
Intervention: Non-invasive OCT based optical angiography
Description: This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
Study NCT02521142 — intervention group
Intervention type: OTHER
Intervention: Oxymap T1
Description: The Oxymap system T1 is installed on a conventional fundus camera (Topcon TRC-50DX), which is operated as for color photography. The Oxymap T1 simultaneously acquires two images of the same area of the fundus at two different wavelengths of light. One of the two wavelengths is sensitive to oxygen saturation, i.e. the light absorbance changes with the oxygen saturation, while the other is insensitive to oxygen saturation and is used to calibrate the light intensity. The two spectral images are automatically processed by the Oxymap Analyzer software. Oxymap Analyzer detects blood vessels and estimates the light absorbance (optical density) at each point along the vessels at each wavelength. The ratio of the optical densities (optical density ratio or ODR) has been shown to be linearly related to hemoglobin oxygen saturation.
Study NCT02033525 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Standard rehabilitation program
Study NCT03262298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD22-CAR-transduced T cells
Description: a single dose of Anti-CD22-CAR-transduced T cells will be infusion after preconditioning.
Study NCT03788265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lipogems
Description: harvest and inject micro-fragment adipose tissue
Study NCT03776903 — intervention group
Intervention type: OTHER
Intervention: ZIKV Detect™ 2.0 IgM Capture ELISA
Description: De-identified archive specimens are tested by ELISA and compared to reference testing (RT-PCR and CDC MAC-ELISA)
Study NCT00252551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteosynthesis
Study NCT02521142 — intervention group
Intervention type: OTHER
Intervention: OCT
Description: non-invasive imaging of retinal and choroidal structures.
Study NCT02521142 — intervention group
Intervention type: OTHER
Intervention: FLA/ICG angiography
Description: Fluorescein Angiography and Indocianine Angiography
Study NCT00252551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple surgery
Description: Surgery without device
Study NCT02347930 — intervention group
Intervention type: OTHER
Intervention: kidney ultrasound
Description: kidney ultrasound
Study NCT00783796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System
Description: Treatment of a maximum of two de novo native coronary artery lesions in small vessels.
Study NCT00704418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac
Description: sterile ophthalmic solution
Study NCT00620750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release injectable naltrexone (Vivitrol)
Description: Three sequential monthly injections of extended release injectable naltrexone (Vivitrol), with option to extend participation for an additional 12 months.
Study NCT03823781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milrinone
Description: The study intervention is an intravenous infusion of milrinone or placebo.
Study NCT03823781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The study intervention is an intravenous infusion of milrinone or placebo.
Study NCT01288274 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community Based administration of DMPA
Description: Injectable contraceptive administered by clinic based health extension worker or community based reproductive health agent using same protocol to test equivalence of community based distribution to facility based distribution
Study NCT06665503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Supplement, probiotic
Description: received oral zinc supplementation; 2.5 ml every 12 hours for children aged \<1 year and 5 ml every 12 hours for older children; the probiotics group received oral probiotics; 1 probiotic sachet
Study NCT06613633 — intervention group
Intervention type: DRUG
Intervention: third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)
Description: Patients with advanced EGFR-mutated NSCLC who met the inclusion criteria and received third-generation EGFR-TKI (monotherapy or combined with brain radiotherapy)
Study NCT02258438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uninterrupted sitting
Description: Subjects will be asked to refrain for two days from any structured activity and to reduce any daily life activity (walking, taking the stairs, biking, etc.) in their daily life. On day 3, subjects will remain seated all day in the room calorimeter, except to rise from the chair to void.
Study NCT02258438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting + 1 bout of activity
Description: Subjects will be asked to perform 45 minutes of moderate-exercise in the morning once per day for two days in their daily life. On day 3 they will remain seated all day in the room calorimeter, except to rise from the chair to void, and to perform one bout of 45-min moderate-intensity (defined below) walking on a treadmill at 1000.
Study NCT02258438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting + microbursts of activity
Description: Subjects will be asked to refrain from any structured exercise for two days but to walk for 5 minutes each hour between 1000 and 1800 in daily life. On day 3, subjects will rise from the seated position every hour for 9 hours from 1000 to 1800 to complete 5min moderate-intensity (defined below) walking on a treadmill, which represents a total of 45min.
Study NCT00704418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile ophthalmic solution
Study NCT02437799 — intervention group
Intervention type: OTHER
Intervention: Dicrotic wave analysis
Description: We will download data from the pulse oximeter that is being used to monitor the patient during their surgery.
Study NCT02220907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin/Canagliflozin
Description: Co-administration of Teneligliptin and Canagliflozin orally once daily for 52 weeks.
Study NCT03410953 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).
Description: The primary immunisation consists of 4 separate 0.5 ml doses administered at the following schedule:~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine
Study NCT02382406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6 IV, D1 for 4 cycles (cycle = 21 days)
Study NCT04477187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Handpiece
Description: Radiofrequency (RF) will travel through the RF generator through the electrodes and into the dermal layer beneath the surface of the skin. The microneedles of the dermal cartridges coupled with the thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.
Study NCT01424930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized low-fat meal and high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14.
Study NCT01424930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
Study NCT02449668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture techniques with a plastic insertion tube was used to introduce every needle. The needles were perpendicularly inserted to a depth of 2-3 cm. The needles were applied to the area of the injured shoulder while the patient was lying in a lateral decubitus position on the stretcher. The skin was prepared with clorhexidine and the needles were sterile. They measured 40 mm long and 0.25 mm in diameter. The sessions lasted 20 minutes and the Qi sensation was sought by consistent manipulations, with rotation of the needles in both senses and scratching of the handle.
Study NCT02449668 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Study NCT00808574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea screening intervention
Description: Brief, theory-based, online assessment of OSA risk followed by risk-tailed OSA presentation.
Study NCT04156165 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VLCD-Active
Description: Lighter life formula products supplied to subjects, four sachets pr day. Dietetic advise given regularly.
Study NCT04156165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maintenance-Active
Description: Weight loss maintenance diet with high protein and low glycemic index and load, high in fiber and whole grain, daily including 150 g minced beef.
Study NCT04156165 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VLCD-Control
Description: Lighter life VLCD products
Study NCT04156165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance-Control
Description: Weight loss maintenance diet with moderate protein and low glycemic index and load, high in fiber and whole grain, daily including 25 g minced beef.
Study NCT01791920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A(Botulax®)
Description: Single administration, Day 0, 20 units
Study NCT01791920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A(Botox®)
Description: Single administration, Day 0, 20units
Study NCT02273830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxygen
Description: Oxygen administered after adjustment during a waking test or at 3L/min
Study NCT02273830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxygen
Description: Oxygen administered after adjustment during a waking test or at 3L/min
Study NCT02417779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Study NCT02417779 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Study NCT02417779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Study NCT02417779 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Description: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
Study NCT01916655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management Care
Description: Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy
Study NCT01916655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management Mobile Care
Description: Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy via mobile phone
Study NCT01916655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: standard and typical CPAP educational and support protocol; is the base level education and support that is provided in the other two interventions in this study.
Study NCT01916655 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: standard and typical CPAP educational and support protocol; is the base level education and support that is provided in the other two interventions in this study.
Study NCT00426608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metyrapone
Description: Metyrapone will be available as 250 mg dose capsule.
Study NCT00426608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprazolam
Description: Alprazolam capsules will be available with dose strength of 0.25mg